Esperion Therapeutics | ESPR - Debt


Esperion Therapeutics reported $262.92M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
Amarin USD 0 0 Mar/2025
Amgen USD 54.6B 17M Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cipla INR 4.38B 231.9M Mar/2025
CSL USD 11.96B 219M Dec/2024
Cytokinetics USD 1.29B 4.48M Mar/2026
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Geron USD 121.99M 76K Dec/2025
Grifols EUR 9.23B 626.05M Dec/2024
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Merck USD 49.34B 7.97B Dec/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 1.31B 571M Dec/2025
Nektar Therapeutics USD 0 0 Jun/2022
Pfizer USD 63.73B 231M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Sanofi EUR 20.33B 1.43B Dec/2025
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024